메뉴 건너뛰기




Volumn 26, Issue 8, 2016, Pages 523-534

213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18–20 September 2015

(22)  Benveniste, Olivier g,h   Rider, Lisa G i   Aggarwal, R a   Allenbach, Y a   Benveniste, O a   De Bleecker, J L a   de Groot, I a   Devilliers, H a   Hilton Jones, D b   Hogrel, J Y a   Lundberg, I E a   Mammen, A L a   Oakley, c   Oddis, C a   Padberg, G d   Ponce, D e   Rose, M R f   Sanner, H a   Selva O'Callaghan, A a   de Visser, M a   more..

e vry   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

EID: 84990929623     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2016.05.014     Document Type: Conference Paper
Times cited : (16)

References (105)
  • 1
    • 84982915259 scopus 로고    scopus 로고
    • High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody
    • pii: aww054; [Epub ahead of print]
    • [1] Allenbach, Y., Keraen, J., Bouvier, A.-M., et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain, 2016 pii: aww054; [Epub ahead of print].
    • (2016) Brain
    • Allenbach, Y.1    Keraen, J.2    Bouvier, A.-M.3
  • 2
    • 1942425614 scopus 로고    scopus 로고
    • 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands
    • [2] Hoogendijk, J.E., Amato, A.A., Lecky, B.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14 (2004), 337–345.
    • (2004) Neuromuscul Disord , vol.14 , pp. 337-345
    • Hoogendijk, J.E.1    Amato, A.A.2    Lecky, B.R.3
  • 3
    • 0041624144 scopus 로고    scopus 로고
    • Unicorns, dragons, polymyositis, and other mythological beasts
    • [3] Amato, A.A., Griggs, R.C., Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 61 (2003), 288–289.
    • (2003) Neurology , vol.61 , pp. 288-289
    • Amato, A.A.1    Griggs, R.C.2
  • 5
    • 22644433770 scopus 로고    scopus 로고
    • Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients
    • [5] Troyanov, Y., Targoff, I.N., Tremblay, J.L., Goulet, J.R., Raymond, Y., Senecal, J.L., Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84 (2005), 231–249.
    • (2005) Medicine (Baltimore) , vol.84 , pp. 231-249
    • Troyanov, Y.1    Targoff, I.N.2    Tremblay, J.L.3    Goulet, J.R.4    Raymond, Y.5    Senecal, J.L.6
  • 6
    • 84939958666 scopus 로고    scopus 로고
    • Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken
    • [6] Benveniste, O., Stenzel, W., Hilton-Jones, D., Sandri, M., Boyer, O., van Engelen, B.G.M., Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol (Berl), 2015, 10.1007/s00401-015-1384-5.
    • (2015) Acta Neuropathol (Berl)
    • Benveniste, O.1    Stenzel, W.2    Hilton-Jones, D.3    Sandri, M.4    Boyer, O.5    van Engelen, B.G.M.6
  • 7
    • 84937514649 scopus 로고    scopus 로고
    • The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy
    • [7] Chung, T., Christopher-Stine, L., Paik, J.J., Corse, A., Mammen, A.L., The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve 52 (2015), 189–195, 10.1002/mus.24642.
    • (2015) Muscle Nerve , vol.52 , pp. 189-195
    • Chung, T.1    Christopher-Stine, L.2    Paik, J.J.3    Corse, A.4    Mammen, A.L.5
  • 8
    • 84975110943 scopus 로고    scopus 로고
    • Myositis-specific autoantibodies: an important tool to support diagnosis of myositis
    • [8] Betteridge, Z., McHugh, N., Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med, 2015, 10.1111/joim.12451.
    • (2015) J Intern Med
    • Betteridge, Z.1    McHugh, N.2
  • 9
    • 84881493692 scopus 로고    scopus 로고
    • Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies
    • [9] Tjärnlund, A., Bottai, M., Rider, L., et al. Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies. Arthritis Rheum, 2012, S323–4.
    • (2012) Arthritis Rheum , pp. S323-4
    • Tjärnlund, A.1    Bottai, M.2    Rider, L.3
  • 10
    • 84905819302 scopus 로고    scopus 로고
    • Evaluation and construction of diagnostic criteria for inclusion body myositis
    • [10] Lloyd, T.E., Mammen, A.L., Amato, A.A., Weiss, M.D., Needham, M., Greenberg, S.A., Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 83 (2014), 426–433, 10.1212/WNL.0000000000000642.
    • (2014) Neurology , vol.83 , pp. 426-433
    • Lloyd, T.E.1    Mammen, A.L.2    Amato, A.A.3    Weiss, M.D.4    Needham, M.5    Greenberg, S.A.6
  • 11
    • 25444454547 scopus 로고    scopus 로고
    • International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies
    • [11] Oddis, C.V., Rider, L.G., Reed, A.M., et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52 (2005), 2607–2615, 10.1002/art.21291.
    • (2005) Arthritis Rheum , vol.52 , pp. 2607-2615
    • Oddis, C.V.1    Rider, L.G.2    Reed, A.M.3
  • 12
    • 84870969044 scopus 로고    scopus 로고
    • Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims
    • [12] U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH), Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf, 2009.
    • (2009)
  • 13
    • 43949087240 scopus 로고    scopus 로고
    • Watch out, watch out, the FDA are about
    • [13] Cano, S.J., Hobart, J.C., Watch out, watch out, the FDA are about. Dev Med Child Neurol 50 (2008), 408–409, 10.1111/j.1469-8749.2008.00408.x.
    • (2008) Dev Med Child Neurol , vol.50 , pp. 408-409
    • Cano, S.J.1    Hobart, J.C.2
  • 14
    • 33846053740 scopus 로고    scopus 로고
    • Challenges in drug development for muscle disease: a stakeholders’ meeting
    • [14] Mendell, J.R., Csimma, C., McDonald, C.M., et al. Challenges in drug development for muscle disease: a stakeholders’ meeting. Muscle Nerve 35 (2007), 8–16, 10.1002/mus.20686.
    • (2007) Muscle Nerve , vol.35 , pp. 8-16
    • Mendell, J.R.1    Csimma, C.2    McDonald, C.M.3
  • 15
    • 77958053448 scopus 로고    scopus 로고
    • Neurologists are from Mars. Rheumatologists are from Venus: differences in approach to classifying the idiopathic inflammatory myopathies
    • [15] Christopher-Stine, L., Neurologists are from Mars. Rheumatologists are from Venus: differences in approach to classifying the idiopathic inflammatory myopathies. Curr Opin Rheumatol 22 (2010), 623–626, 10.1097/BOR.0b013e32833f8f72.
    • (2010) Curr Opin Rheumatol , vol.22 , pp. 623-626
    • Christopher-Stine, L.1
  • 16
    • 9144261114 scopus 로고    scopus 로고
    • International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
    • [16] Isenberg, D.A., Allen, E., Farewell, V., et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43 (2004), 49–54, 10.1093/rheumatology/keg427.
    • (2004) Rheumatology (Oxford) , vol.43 , pp. 49-54
    • Isenberg, D.A.1    Allen, E.2    Farewell, V.3
  • 17
    • 0035179180 scopus 로고    scopus 로고
    • Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies
    • [17] Miller, F.W., Rider, L.G., Chung, Y.L., et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40 (2001), 1262–1273.
    • (2001) Rheumatology (Oxford) , vol.40 , pp. 1262-1273
    • Miller, F.W.1    Rider, L.G.2    Chung, Y.L.3
  • 18
    • 3142680150 scopus 로고    scopus 로고
    • International consensus on preliminary definitions of improvement in adult and juvenile myositis
    • [18] Rider, L.G., Giannini, E.H., Brunner, H.I., et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50 (2004), 2281–2290.
    • (2004) Arthritis Rheum , vol.50 , pp. 2281-2290
    • Rider, L.G.1    Giannini, E.H.2    Brunner, H.I.3
  • 19
    • 80855165422 scopus 로고    scopus 로고
    • Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)
    • [19] Rider, L.G., Werth, V.P., Huber, A.M., et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 63:Suppl. 11 (2011), S118–57, 10.1002/acr.20532.
    • (2011) Arthritis Care Res , vol.63 , pp. S118-57
    • Rider, L.G.1    Werth, V.P.2    Huber, A.M.3
  • 20
    • 0036867768 scopus 로고    scopus 로고
    • Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies
    • [20] Rider, L.G., Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 28 (2002), 935–977.
    • (2002) Rheum Dis Clin North Am , vol.28 , pp. 935-977
    • Rider, L.G.1
  • 21
    • 0347927297 scopus 로고    scopus 로고
    • Defining clinical improvement in adult and juvenile myositis
    • [21] Rider, L.G., Giannini, E.H., Harris-Love, M., et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 30 (2003), 603–617.
    • (2003) J Rheumatol , vol.30 , pp. 603-617
    • Rider, L.G.1    Giannini, E.H.2    Harris-Love, M.3
  • 22
    • 84873878655 scopus 로고    scopus 로고
    • Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial
    • [22] Oddis, C.V., Reed, A.M., Aggarwal, R., et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65 (2013), 314–324, 10.1002/art.37754.
    • (2013) Arthritis Rheum , vol.65 , pp. 314-324
    • Oddis, C.V.1    Reed, A.M.2    Aggarwal, R.3
  • 23
    • 84990951473 scopus 로고    scopus 로고
    • Lay report: outcome measures and clinical trial readiness in idiopathic inflammatory myopathies
    • September 18–20, 2015, Heemskerk, The Netherlands n.d.
    • [23] Lay report: outcome measures and clinical trial readiness in idiopathic inflammatory myopathies. September 18–20, 2015, Heemskerk, The Netherlands http://www.enmc.org/publications/workshop-reports/outcome-measures-and-clinical-trial-readiness-idiopathic-inflammatory-myopathies-iim n.d.
  • 24
    • 84884983123 scopus 로고    scopus 로고
    • ENMC myositis muscle biopsy study group. 193rd ENMC international workshop pathology diagnosis of idiopathic inflammatory myopathies 30 November-2 December 2012, Naarden, The Netherlands
    • [24] De Bleecker, J.L., Lundberg, I.E., de Visser, M., ENMC myositis muscle biopsy study group. 193rd ENMC international workshop pathology diagnosis of idiopathic inflammatory myopathies 30 November-2 December 2012, Naarden, The Netherlands. Neuromuscul Disord 23 (2013), 945–951, 10.1016/j.nmd.2013.07.007.
    • (2013) Neuromuscul Disord , vol.23 , pp. 945-951
    • De Bleecker, J.L.1    Lundberg, I.E.2    de Visser, M.3
  • 25
    • 84924337345 scopus 로고    scopus 로고
    • 205th ENMC international workshop: pathology diagnosis of idiopathic inflammatory myopathies Part II 28–30 March 2014, Naarden, The Netherlands
    • [25] De Bleecker, J.L., De Paepe, B., Aronica, E., et al. 205th ENMC international workshop: pathology diagnosis of idiopathic inflammatory myopathies Part II 28–30 March 2014, Naarden, The Netherlands. Neuromuscul Disord 25 (2015), 268–272, 10.1016/j.nmd.2014.12.001.
    • (2015) Neuromuscul Disord , vol.25 , pp. 268-272
    • De Bleecker, J.L.1    De Paepe, B.2    Aronica, E.3
  • 26
    • 84929938733 scopus 로고    scopus 로고
    • Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy
    • [26] Aouizerate, J., De Antonio, M., Bassez, G., et al. Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol Commun, 2, 2014, 154, 10.1186/s40478-014-0154-2.
    • (2014) Acta Neuropathol Commun , vol.2 , pp. 154
    • Aouizerate, J.1    De Antonio, M.2    Bassez, G.3
  • 27
    • 84940743653 scopus 로고    scopus 로고
    • Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis
    • [27] Mescam-Mancini, L., Allenbach, Y., Hervier, B., et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 138 (2015), 2485–2492, 10.1093/brain/awv192.
    • (2015) Brain , vol.138 , pp. 2485-2492
    • Mescam-Mancini, L.1    Allenbach, Y.2    Hervier, B.3
  • 28
    • 84931052750 scopus 로고    scopus 로고
    • Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy
    • [28] Stenzel, W., Preuße, C., Allenbach, Y., et al. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology 84:13 (2015), 1346–1354, 10.1212/WNL.0000000000001422.
    • (2015) Neurology , vol.84 , Issue.13 , pp. 1346-1354
    • Stenzel, W.1    Preuße, C.2    Allenbach, Y.3
  • 29
    • 84959016568 scopus 로고    scopus 로고
    • Dermatomyositis with or without anti-melanoma differentiation-associated protein 5 antibodies: common interferon signature but distinct NOS2 expression
    • [29] Allenbach, Y., Leroux, G., Calvet, X.S., et al. Dermatomyositis with or without anti-melanoma differentiation-associated protein 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol 186:3 (2016), 691–700, 10.1016/j.ajpath.2015.11.010.
    • (2016) Am J Pathol , vol.186 , Issue.3 , pp. 691-700
    • Allenbach, Y.1    Leroux, G.2    Calvet, X.S.3
  • 30
    • 84940656454 scopus 로고    scopus 로고
    • The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis
    • [30] Pinal-Fernandez, I., Casciola-Rosen, L.A., Christopher-Stine, L., Corse, A.M., Mammen, A.L., The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 42 (2015), 1448–1454.
    • (2015) J Rheumatol , vol.42 , pp. 1448-1454
    • Pinal-Fernandez, I.1    Casciola-Rosen, L.A.2    Christopher-Stine, L.3    Corse, A.M.4    Mammen, A.L.5
  • 31
    • 77953373228 scopus 로고    scopus 로고
    • A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy
    • [31] Christopher-Stine, L., Casciola-Rosen, L.A., Hong, G., Chung, T., Corse, A.M., Mammen, A.L., A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62 (2010), 2757–2766, 10.1002/art.27572.
    • (2010) Arthritis Rheum , vol.62 , pp. 2757-2766
    • Christopher-Stine, L.1    Casciola-Rosen, L.A.2    Hong, G.3    Chung, T.4    Corse, A.M.5    Mammen, A.L.6
  • 32
    • 0026354417 scopus 로고
    • A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups
    • [32] Love, L.A., Leff, R.L., Fraser, D.D., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70 (1991), 360–374.
    • (1991) Medicine (Baltimore) , vol.70 , pp. 360-374
    • Love, L.A.1    Leff, R.L.2    Fraser, D.D.3
  • 33
    • 78651399830 scopus 로고    scopus 로고
    • Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies
    • [33] Rider, L.G., Miller, F.W., Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305 (2011), 183–190, 10.1001/jama.2010.1977.
    • (2011) JAMA , vol.305 , pp. 183-190
    • Rider, L.G.1    Miller, F.W.2
  • 34
    • 0016638734 scopus 로고
    • Polymyositis and dermatomyositis (second of two parts)
    • [34] Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292 (1975), 403–407, 10.1056/NEJM197502202920807.
    • (1975) N Engl J Med , vol.292 , pp. 403-407
    • Bohan, A.1    Peter, J.B.2
  • 35
    • 20944450759 scopus 로고    scopus 로고
    • Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis
    • [35] Greenberg, S.A., Pinkus, J.L., Pinkus, G.S., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57 (2005), 664–678.
    • (2005) Ann Neurol , vol.57 , pp. 664-678
    • Greenberg, S.A.1    Pinkus, J.L.2    Pinkus, G.S.3
  • 36
    • 84902367750 scopus 로고    scopus 로고
    • Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis
    • [36] Suárez-Calvet, X., Gallardo, E., Nogales-Gadea, G., et al. Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. J Pathol 233 (2014), 258–268, 10.1002/path.4346.
    • (2014) J Pathol , vol.233 , pp. 258-268
    • Suárez-Calvet, X.1    Gallardo, E.2    Nogales-Gadea, G.3
  • 37
    • 84964528178 scopus 로고    scopus 로고
    • Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis
    • [37] Moghadam-Kia, S., Oddis, C.V., Sato, S., Kuwana, M., Aggarwal, R., Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res, 2015, 10.1002/acr.22728.
    • (2015) Arthritis Care Res
    • Moghadam-Kia, S.1    Oddis, C.V.2    Sato, S.3    Kuwana, M.4    Aggarwal, R.5
  • 38
    • 84856402970 scopus 로고    scopus 로고
    • Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis
    • [38] Trallero-Araguás, E., Rodrigo-Pendás, J.Á., Selva-O'Callaghan, A., et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 64 (2012), 523–532, 10.1002/art.33379.
    • (2012) Arthritis Rheum , vol.64 , pp. 523-532
    • Trallero-Araguás, E.1    Rodrigo-Pendás, J.Á.2    Selva-O'Callaghan, A.3
  • 39
    • 79953837289 scopus 로고    scopus 로고
    • Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study
    • [39] Hamaguchi, Y., Kuwana, M., Hoshino, K., et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147 (2011), 391–398, 10.1001/archdermatol.2011.52.
    • (2011) Arch Dermatol , vol.147 , pp. 391-398
    • Hamaguchi, Y.1    Kuwana, M.2    Hoshino, K.3
  • 40
    • 84957900878 scopus 로고    scopus 로고
    • Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial
    • [40] Ruperto, N., Pistorio, A., Oliveira, S., et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 387 (2016), 671–678, 10.1016/S0140-6736(15)01021-1.
    • (2016) Lancet , vol.387 , pp. 671-678
    • Ruperto, N.1    Pistorio, A.2    Oliveira, S.3
  • 41
    • 84990932862 scopus 로고    scopus 로고
    • P.21.9 Responsiveness of muscle testing and functions in a retrospective 51 inflammatory myopathies patient series
    • [41] Devilliers, H., Shewaro, N., Allenbach, Y., Rigolet, A., Benveniste, O., P.21.9 Responsiveness of muscle testing and functions in a retrospective 51 inflammatory myopathies patient series. Neuromuscul Disord, 23, 2013, 846, 10.1016/j.nmd.2013.06.714.
    • (2013) Neuromuscul Disord , vol.23 , pp. 846
    • Devilliers, H.1    Shewaro, N.2    Allenbach, Y.3    Rigolet, A.4    Benveniste, O.5
  • 42
    • 84860606496 scopus 로고    scopus 로고
    • Modifying the Medical Research Council grading system through Rasch analyses
    • [42] Vanhoutte, E.K., Faber, C.G., van Nes, S.I., et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain 135 (2012), 1639–1649, 10.1093/brain/awr318.
    • (2012) Brain , vol.135 , pp. 1639-1649
    • Vanhoutte, E.K.1    Faber, C.G.2    van Nes, S.I.3
  • 43
    • 84922311710 scopus 로고    scopus 로고
    • Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial
    • e0113999
    • [43] Seferian, A.M., Moraux, A., Annoussamy, M., et al. Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial. PLoS ONE, 10, 2015, 10.1371/journal.pone.0113999 e0113999.
    • (2015) PLoS ONE , vol.10
    • Seferian, A.M.1    Moraux, A.2    Annoussamy, M.3
  • 44
    • 84929462260 scopus 로고    scopus 로고
    • Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial
    • e0121799
    • [44] Seferian, A.M., Moraux, A., Canal, A., et al. Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial. PLoS ONE, 10, 2015, 10.1371/journal.pone.0121799 e0121799.
    • (2015) PLoS ONE , vol.10
    • Seferian, A.M.1    Moraux, A.2    Canal, A.3
  • 45
    • 84868110471 scopus 로고    scopus 로고
    • Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis
    • [45] Allenbach, Y., Benveniste, O., Decostre, V., et al. Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. Neuromuscul Disord 22 (2012), 980–986, 10.1016/j.nmd.2012.05.004.
    • (2012) Neuromuscul Disord , vol.22 , pp. 980-986
    • Allenbach, Y.1    Benveniste, O.2    Decostre, V.3
  • 46
    • 84901983707 scopus 로고    scopus 로고
    • Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials
    • [46] Hogrel, J.-Y., Allenbach, Y., Canal, A., et al. Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials. Neuromuscul Disord 24 (2014), 604–610, 10.1016/j.nmd.2014.04.009.
    • (2014) Neuromuscul Disord , vol.24 , pp. 604-610
    • Hogrel, J.-Y.1    Allenbach, Y.2    Canal, A.3
  • 47
    • 81055125519 scopus 로고    scopus 로고
    • Long-term observational study of sporadic inclusion body myositis
    • [47] Benveniste, O., Guiguet, M., Freebody, J., et al. Long-term observational study of sporadic inclusion body myositis. Brain 134 (2011), 3176–3184, 10.1093/brain/awr213.
    • (2011) Brain , vol.134 , pp. 3176-3184
    • Benveniste, O.1    Guiguet, M.2    Freebody, J.3
  • 48
    • 41849098898 scopus 로고    scopus 로고
    • Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity
    • [48] Jackson, C.E., Barohn, R.J., Gronseth, G., Pandya, S., Herbelin, L., Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 37 (2008), 473–476, 10.1002/mus.20958.
    • (2008) Muscle Nerve , vol.37 , pp. 473-476
    • Jackson, C.E.1    Barohn, R.J.2    Gronseth, G.3    Pandya, S.4    Herbelin, L.5
  • 49
    • 85062117974 scopus 로고    scopus 로고
    • Wrist-worn accelerometer as innovative tool for longitudinal follow-up of idiopathic inflammatory myopathy patients: a pilot study
    • [49] Allenbach, Y., Foucher, A., Champtiaux, N., et al. Wrist-worn accelerometer as innovative tool for longitudinal follow-up of idiopathic inflammatory myopathy patients: a pilot study. Neuromuscul Disord, 25, 2015, S310, 10.1016/j.nmd.2015.06.442.
    • (2015) Neuromuscul Disord , vol.25 , pp. S310
    • Allenbach, Y.1    Foucher, A.2    Champtiaux, N.3
  • 50
    • 34248206210 scopus 로고    scopus 로고
    • IMACS website
    • n.d.
    • [50] IMACS website. http://www.niehs.nih.gov/research/resources/imacs/diseaseactivity/index.cfm n.d.
  • 51
    • 77950386566 scopus 로고    scopus 로고
    • Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies
    • [51] Rider, L.G., Koziol, D., Giannini, E.H., et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 62 (2010), 465–472, 10.1002/acr.20035.
    • (2010) Arthritis Care Res , vol.62 , pp. 465-472
    • Rider, L.G.1    Koziol, D.2    Giannini, E.H.3
  • 52
    • 80052596202 scopus 로고    scopus 로고
    • A randomized, pilot trial of etanercept in dermatomyositis
    • [52] Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70 (2011), 427–436, 10.1002/ana.22477.
    • (2011) Ann Neurol , vol.70 , pp. 427-436
  • 53
    • 84907578519 scopus 로고    scopus 로고
    • Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial
    • [53] Rider, L.G., Yip, A.L., Horkayne-Szakaly, I., et al. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol 32 (2014), 689–696.
    • (2014) Clin Exp Rheumatol , vol.32 , pp. 689-696
    • Rider, L.G.1    Yip, A.L.2    Horkayne-Szakaly, I.3
  • 54
    • 0036842954 scopus 로고    scopus 로고
    • Development of the myositis activities profile – validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis
    • [54] Alexanderson, H., Lundberg, I.E., Stenström, C.H., Development of the myositis activities profile – validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol 29 (2002), 2386–2392.
    • (2002) J Rheumatol , vol.29 , pp. 2386-2392
    • Alexanderson, H.1    Lundberg, I.E.2    Stenström, C.H.3
  • 55
    • 12344327640 scopus 로고    scopus 로고
    • Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis
    • [55] Ponyi, A., Borgulya, G., Constantin, T., Váncsa, A., Gergely, L., Dankó, K., Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 44 (2005), 83–88, 10.1093/rheumatology/keh404.
    • (2005) Rheumatology (Oxford) , vol.44 , pp. 83-88
    • Ponyi, A.1    Borgulya, G.2    Constantin, T.3    Váncsa, A.4    Gergely, L.5    Dankó, K.6
  • 56
    • 2342500841 scopus 로고    scopus 로고
    • Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies
    • [56] Huber, A.M., Feldman, B.M., Rennebohm, R.M., et al. Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 50 (2004), 1595–1603, 10.1002/art.20179.
    • (2004) Arthritis Rheum , vol.50 , pp. 1595-1603
    • Huber, A.M.1    Feldman, B.M.2    Rennebohm, R.M.3
  • 57
    • 38649141175 scopus 로고    scopus 로고
    • The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study
    • [57] Ruperto, N., Ravelli, A., Pistorio, A., et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59 (2008), 4–13, 10.1002/art.23248.
    • (2008) Arthritis Rheum , vol.59 , pp. 4-13
    • Ruperto, N.1    Ravelli, A.2    Pistorio, A.3
  • 58
    • 32544453552 scopus 로고    scopus 로고
    • Functional index-2: validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis
    • [58] Alexanderson, H., Broman, L., Tollbäck, A., Josefson, A., Lundberg, I.E., Stenström, C.H., Functional index-2: validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 55 (2006), 114–122, 10.1002/art.21715.
    • (2006) Arthritis Rheum , vol.55 , pp. 114-122
    • Alexanderson, H.1    Broman, L.2    Tollbäck, A.3    Josefson, A.4    Lundberg, I.E.5    Stenström, C.H.6
  • 60
    • 84902547648 scopus 로고    scopus 로고
    • Activity rating scales in adult muscle disease: what do they actually measure?
    • [60] Seedat, F., James, M.K., Rose, M.R., Activity rating scales in adult muscle disease: what do they actually measure?. Muscle Nerve 50 (2014), 14–23, 10.1002/mus.24093.
    • (2014) Muscle Nerve , vol.50 , pp. 14-23
    • Seedat, F.1    James, M.K.2    Rose, M.R.3
  • 61
    • 84902538078 scopus 로고    scopus 로고
    • Activity rating scales in adult muscle disease: how well do they actually measure?
    • [61] Seedat, F., James, M.K., Rose, M.R., Activity rating scales in adult muscle disease: how well do they actually measure?. Muscle Nerve 50 (2014), 24–33, 10.1002/mus.24090.
    • (2014) Muscle Nerve , vol.50 , pp. 24-33
    • Seedat, F.1    James, M.K.2    Rose, M.R.3
  • 62
    • 84991012508 scopus 로고    scopus 로고
    • A consensus hybrid definition using a conjoint analysis is the proposed as response criteria for minimal and moderate improvement for adult polymyositis and dermatomyositis clinical trials
    • [62] Aggarwal, R., Rider, L., Ruperto, N., et al. A consensus hybrid definition using a conjoint analysis is the proposed as response criteria for minimal and moderate improvement for adult polymyositis and dermatomyositis clinical trials. Arthritis Rheumatol Suppl, 2014, S404.
    • (2014) Arthritis Rheumatol Suppl , pp. S404
    • Aggarwal, R.1    Rider, L.2    Ruperto, N.3
  • 63
    • 84991012502 scopus 로고    scopus 로고
    • A hybrid conjoint analysis model is proposed as the definition of minimal, moderate and major clinical improvement in juvenile dermatomyositis clinical trials
    • [63] Rider, L., Aggarwal, R., Bayat, N., et al. A hybrid conjoint analysis model is proposed as the definition of minimal, moderate and major clinical improvement in juvenile dermatomyositis clinical trials. Arthritis Rheumatol Suppl, 2014, S578.
    • (2014) Arthritis Rheumatol Suppl , pp. S578
    • Rider, L.1    Aggarwal, R.2    Bayat, N.3
  • 64
    • 83455203358 scopus 로고    scopus 로고
    • Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UK
    • [64] Sadjadi, R., Vincent, K.A., Carr, A.J., et al. Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UK. Health Qual Life Outcomes, 9, 2011, 114, 10.1186/1477-7525-9-114.
    • (2011) Health Qual Life Outcomes , vol.9 , pp. 114
    • Sadjadi, R.1    Vincent, K.A.2    Carr, A.J.3
  • 65
    • 77955826139 scopus 로고    scopus 로고
    • Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases
    • [65] Sansone, V.A., Panzeri, M., Montanari, M., et al. Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases. Eur J Neurol 17 (2010), 1178–1187, 10.1111/j.1468-1331.2010.02992.x.
    • (2010) Eur J Neurol , vol.17 , pp. 1178-1187
    • Sansone, V.A.1    Panzeri, M.2    Montanari, M.3
  • 66
    • 34548567599 scopus 로고    scopus 로고
    • Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy
    • [66] Stone, K.B., Oddis, C.V., Fertig, N., et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 56 (2007), 3125–3131, 10.1002/art.22865.
    • (2007) Arthritis Rheum , vol.56 , pp. 3125-3131
    • Stone, K.B.1    Oddis, C.V.2    Fertig, N.3
  • 67
    • 55849084286 scopus 로고    scopus 로고
    • Reliability and validity of the myositis disease activity assessment tool
    • [67] Sultan, S.M., Allen, E., Oddis, C.V., et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 58 (2008), 3593–3599, 10.1002/art.23963.
    • (2008) Arthritis Rheum , vol.58 , pp. 3593-3599
    • Sultan, S.M.1    Allen, E.2    Oddis, C.V.3
  • 68
    • 84898849450 scopus 로고    scopus 로고
    • Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
    • [68] Saketkoo, L.A., Mittoo, S., Huscher, D., et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 69 (2014), 436–444, 10.1136/thoraxjnl-2013-204202.
    • (2014) Thorax , vol.69 , pp. 436-444
    • Saketkoo, L.A.1    Mittoo, S.2    Huscher, D.3
  • 69
    • 51849151225 scopus 로고    scopus 로고
    • Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis
    • [69] Klein, R.Q., Bangert, C.A., Costner, M., et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 159 (2008), 887–894, 10.1111/j.1365-2133.2008.08711.x.
    • (2008) Br J Dermatol , vol.159 , pp. 887-894
    • Klein, R.Q.1    Bangert, C.A.2    Costner, M.3
  • 70
    • 84946491330 scopus 로고    scopus 로고
    • Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change
    • [70] Anyanwu, C.O., Fiorentino, D.F., Chung, L., et al. Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol 173 (2015), 969–974, 10.1111/bjd.13915.
    • (2015) Br J Dermatol , vol.173 , pp. 969-974
    • Anyanwu, C.O.1    Fiorentino, D.F.2    Chung, L.3
  • 71
    • 84920822898 scopus 로고    scopus 로고
    • Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life
    • [71] Robinson, E.S., Feng, R., Okawa, J., Werth, V.P., Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. Br J Dermatol, 2014, 10.1111/bjd.13167.
    • (2014) Br J Dermatol
    • Robinson, E.S.1    Feng, R.2    Okawa, J.3    Werth, V.P.4
  • 72
    • 81155131224 scopus 로고    scopus 로고
    • Quality of life in dermatomyositis
    • [72] Goreshi, R., Chock, M., Foering, K., et al. Quality of life in dermatomyositis. J Am Acad Dermatol 65 (2011), 1107–1116, 10.1016/j.jaad.2010.10.016.
    • (2011) J Am Acad Dermatol , vol.65 , pp. 1107-1116
    • Goreshi, R.1    Chock, M.2    Foering, K.3
  • 73
    • 84948822903 scopus 로고    scopus 로고
    • Patients’ experience of myositis and further validation of a myositis-specific patient reported outcome measure – establishing core domains and expanding patient input on clinical assessment in myositis. Report from OMERACT 12
    • [73] Regardt, M., Basharat, P., Christopher-Stine, L., et al. Patients’ experience of myositis and further validation of a myositis-specific patient reported outcome measure – establishing core domains and expanding patient input on clinical assessment in myositis. Report from OMERACT 12. J Rheumatol 42 (2015), 2492–2495, 10.3899/jrheum.141243.
    • (2015) J Rheumatol , vol.42 , pp. 2492-2495
    • Regardt, M.1    Basharat, P.2    Christopher-Stine, L.3
  • 75
    • 70350546006 scopus 로고    scopus 로고
    • Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index
    • [75] Rider, L.G., Lachenbruch, P.A., Monroe, J.B., et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 60 (2009), 3425–3435, 10.1002/art.24904.
    • (2009) Arthritis Rheum , vol.60 , pp. 3425-3435
    • Rider, L.G.1    Lachenbruch, P.A.2    Monroe, J.B.3
  • 76
    • 79957644229 scopus 로고    scopus 로고
    • Interrater reliability and aspects of validity of the myositis damage index
    • [76] Sultan, S.M., Allen, E., Cooper, R.G., et al. Interrater reliability and aspects of validity of the myositis damage index. Ann Rheum Dis 70 (2011), 1272–1276, 10.1136/ard.2010.142117.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1272-1276
    • Sultan, S.M.1    Allen, E.2    Cooper, R.G.3
  • 77
    • 84901759236 scopus 로고    scopus 로고
    • A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
    • [77] King, T.E., Bradford, W.Z., Castro-Bernardini, S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2083–2092, 10.1056/NEJMoa1402582.
    • (2014) N Engl J Med , vol.370 , pp. 2083-2092
    • King, T.E.1    Bradford, W.Z.2    Castro-Bernardini, S.3
  • 78
    • 84901810710 scopus 로고    scopus 로고
    • Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
    • [78] Richeldi, L., du Bois, R.M., Raghu, G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082, 10.1056/NEJMoa1402584.
    • (2014) N Engl J Med , vol.370 , pp. 2071-2082
    • Richeldi, L.1    du Bois, R.M.2    Raghu, G.3
  • 79
    • 36249001195 scopus 로고    scopus 로고
    • Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
    • [79] Tashkin, D.P., Elashoff, R., Clements, P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 (2007), 1026–1034, 10.1164/rccm.200702-326OC.
    • (2007) Am J Respir Crit Care Med , vol.176 , pp. 1026-1034
    • Tashkin, D.P.1    Elashoff, R.2    Clements, P.J.3
  • 80
    • 44449152061 scopus 로고    scopus 로고
    • Interstitial lung disease in systemic sclerosis: a simple staging system
    • [80] Goh, N.S.L., Desai, S.R., Veeraraghavan, S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177 (2008), 1248–1254, 10.1164/rccm.200706-877OC.
    • (2008) Am J Respir Crit Care Med , vol.177 , pp. 1248-1254
    • Goh, N.S.L.1    Desai, S.R.2    Veeraraghavan, S.3
  • 81
    • 77956621760 scopus 로고    scopus 로고
    • Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials
    • [81] Khanna, D., Brown, K.K., Clements, P.J., et al. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol 28 (2010), S55–62.
    • (2010) Clin Exp Rheumatol , vol.28 , pp. S55-62
    • Khanna, D.1    Brown, K.K.2    Clements, P.J.3
  • 82
    • 77951170794 scopus 로고    scopus 로고
    • Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
    • [82] Zappala, C.J., Latsi, P.I., Nicholson, A.G., et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 35 (2010), 830–836, 10.1183/09031936.00155108.
    • (2010) Eur Respir J , vol.35 , pp. 830-836
    • Zappala, C.J.1    Latsi, P.I.2    Nicholson, A.G.3
  • 83
    • 84858297473 scopus 로고    scopus 로고
    • Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM
    • [83] Goreshi, R., Okawa, J., Rose, M., et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol 132 (2012), 1117–1124, 10.1038/jid.2011.440.
    • (2012) J Invest Dermatol , vol.132 , pp. 1117-1124
    • Goreshi, R.1    Okawa, J.2    Rose, M.3
  • 84
    • 40849135734 scopus 로고    scopus 로고
    • Juvenile dermatomyositis disease activity collaborative study group. Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: results using abbreviated formats
    • [84] Huber, A.M., Lachenbruch, P.A., Dugan, E.M., Miller, F.W., Rider, L.G., Juvenile dermatomyositis disease activity collaborative study group. Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum 59 (2008), 352–356, 10.1002/art.23313.
    • (2008) Arthritis Rheum , vol.59 , pp. 352-356
    • Huber, A.M.1    Lachenbruch, P.A.2    Dugan, E.M.3    Miller, F.W.4    Rider, L.G.5
  • 85
    • 39449137046 scopus 로고    scopus 로고
    • Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis
    • [85] Huber, A.M., Dugan, E.M., Lachenbruch, P.A., et al. Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis. Arthritis Rheum 59 (2008), 214–221, 10.1002/art.23340.
    • (2008) Arthritis Rheum , vol.59 , pp. 214-221
    • Huber, A.M.1    Dugan, E.M.2    Lachenbruch, P.A.3
  • 86
    • 84880288386 scopus 로고    scopus 로고
    • The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies
    • [86] Rider, L.G., Shah, M., Mamyrova, G., et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92 (2013), 223–243, 10.1097/MD.0b013e31829d08f9.
    • (2013) Medicine (Baltimore) , vol.92 , pp. 223-243
    • Rider, L.G.1    Shah, M.2    Mamyrova, G.3
  • 87
    • 84876101120 scopus 로고    scopus 로고
    • Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?
    • [87] Tansley, S.L., McHugh, N.J., Wedderburn, L.R., Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?. Arthritis Res Ther, 15, 2013, 211, 10.1186/ar4198.
    • (2013) Arthritis Res Ther , vol.15 , pp. 211
    • Tansley, S.L.1    McHugh, N.J.2    Wedderburn, L.R.3
  • 88
    • 75649089647 scopus 로고    scopus 로고
    • Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset
    • [88] Sanner, H., Gran, J.-T., Sjaastad, I., Flatø, B., Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 48 (2009), 1541–1547, 10.1093/rheumatology/kep302.
    • (2009) Rheumatology (Oxford) , vol.48 , pp. 1541-1547
    • Sanner, H.1    Gran, J.-T.2    Sjaastad, I.3    Flatø, B.4
  • 89
    • 84906827500 scopus 로고    scopus 로고
    • Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool
    • [89] Sanner, H., Sjaastad, I., Flatø, B., Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford) 53 (2014), 1578–1585, 10.1093/rheumatology/keu146.
    • (2014) Rheumatology (Oxford) , vol.53 , pp. 1578-1585
    • Sanner, H.1    Sjaastad, I.2    Flatø, B.3
  • 90
    • 84863422766 scopus 로고    scopus 로고
    • Quality of life in adults with juvenile-onset dermatomyositis: a case-control study
    • [90] Tollisen, A., Sanner, H., Flatø, B., Wahl, A.K., Quality of life in adults with juvenile-onset dermatomyositis: a case-control study. Arthritis Care Res 64 (2012), 1020–1027, 10.1002/acr.21637.
    • (2012) Arthritis Care Res , vol.64 , pp. 1020-1027
    • Tollisen, A.1    Sanner, H.2    Flatø, B.3    Wahl, A.K.4
  • 91
    • 77955300026 scopus 로고    scopus 로고
    • Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a case-control study
    • [91] Sanner, H., Kirkhus, E., Merckoll, E., et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a case-control study. Arthritis Care Res 62 (2010), 1103–1111, 10.1002/acr.20203.
    • (2010) Arthritis Care Res , vol.62 , pp. 1103-1111
    • Sanner, H.1    Kirkhus, E.2    Merckoll, E.3
  • 92
  • 93
    • 79953301131 scopus 로고    scopus 로고
    • Cardiac dysfunction in juvenile dermatomyositis: a case-control study
    • [93] Schwartz, T., Sanner, H., Husebye, T., Flatø, B., Sjaastad, I., Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 70 (2011), 766–771, 10.1136/ard.2010.137968.
    • (2011) Ann Rheum Dis , vol.70 , pp. 766-771
    • Schwartz, T.1    Sanner, H.2    Husebye, T.3    Flatø, B.4    Sjaastad, I.5
  • 94
    • 84881053453 scopus 로고    scopus 로고
    • In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity
    • [94] Schwartz, T., Sanner, H., Gjesdal, O., Flatø, B., Sjaastad, I., In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. Ann Rheum Dis 73 (2014), 1805–1810, 10.1136/annrheumdis-2013-203279.
    • (2014) Ann Rheum Dis , vol.73 , pp. 1805-1810
    • Schwartz, T.1    Sanner, H.2    Gjesdal, O.3    Flatø, B.4    Sjaastad, I.5
  • 95
    • 33750306690 scopus 로고    scopus 로고
    • Long-term outcome in polymyositis and dermatomyositis
    • [95] Bronner, I.M., van der Meulen, M.F.G., de Visser, M., et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 65 (2006), 1456–1461, 10.1136/ard.2005.045690.
    • (2006) Ann Rheum Dis , vol.65 , pp. 1456-1461
    • Bronner, I.M.1    van der Meulen, M.F.G.2    de Visser, M.3
  • 96
    • 0034917111 scopus 로고    scopus 로고
    • A comparative study of outcome in myositis and other musculoskeletal disorders assessed using the Nottingham health profile
    • [96] Chung, Y.L., Mitchell, H.L., Houssien, D.A., Al-Mahrouki, H., Carr, A.J., Scott, D.L., A comparative study of outcome in myositis and other musculoskeletal disorders assessed using the Nottingham health profile. Clin Exp Rheumatol 19 (2001), 447–450.
    • (2001) Clin Exp Rheumatol , vol.19 , pp. 447-450
    • Chung, Y.L.1    Mitchell, H.L.2    Houssien, D.A.3    Al-Mahrouki, H.4    Carr, A.J.5    Scott, D.L.6
  • 97
    • 79952010715 scopus 로고    scopus 로고
    • Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study
    • [97] Regardt, M., Welin Henriksson, E., Alexanderson, H., Lundberg, I.E., Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study. Rheumatology (Oxford) 50 (2011), 578–585, 10.1093/rheumatology/keq356.
    • (2011) Rheumatology (Oxford) , vol.50 , pp. 578-585
    • Regardt, M.1    Welin Henriksson, E.2    Alexanderson, H.3    Lundberg, I.E.4
  • 98
    • 0036108902 scopus 로고    scopus 로고
    • Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality
    • [98] Sultan, S.M., Ioannou, Y., Moss, K., Isenberg, D.A., Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41 (2002), 22–26.
    • (2002) Rheumatology (Oxford) , vol.41 , pp. 22-26
    • Sultan, S.M.1    Ioannou, Y.2    Moss, K.3    Isenberg, D.A.4
  • 99
    • 80755181023 scopus 로고    scopus 로고
    • Adult measures of general health and health-related quality of life: medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL)
    • [99] Busija, L., Pausenberger, E., Haines, T.P., Haymes, S., Buchbinder, R., Osborne, R.H., Adult measures of general health and health-related quality of life: medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res 63:Suppl. 11 (2011), S383–412, 10.1002/acr.20541.
    • (2011) Arthritis Care Res , vol.63 , pp. S383-412
    • Busija, L.1    Pausenberger, E.2    Haines, T.P.3    Haymes, S.4    Buchbinder, R.5    Osborne, R.H.6
  • 100
    • 34147108157 scopus 로고    scopus 로고
    • Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL)
    • [100] Vincent, K.A., Carr, A.J., Walburn, J., Scott, D.L., Rose, M.R., Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 68 (2007), 1051–1057, 10.1212/01.wnl.0000257819.47628.41.
    • (2007) Neurology , vol.68 , pp. 1051-1057
    • Vincent, K.A.1    Carr, A.J.2    Walburn, J.3    Scott, D.L.4    Rose, M.R.5
  • 101
    • 84896735828 scopus 로고    scopus 로고
    • Dependent and paranoid personality patterns in myotonic dystrophy type 1
    • [101] Peric, S., Sreckov, M., Basta, I., et al. Dependent and paranoid personality patterns in myotonic dystrophy type 1. Acta Neurol Scand 129 (2014), 219–225, 10.1111/ane.12173.
    • (2014) Acta Neurol Scand , vol.129 , pp. 219-225
    • Peric, S.1    Sreckov, M.2    Basta, I.3
  • 102
    • 84925356272 scopus 로고    scopus 로고
    • The individualized neuromuscular quality of life questionnaire: cultural translation and psychometric validation for the Dutch population
    • [102] Seesing, F.M., van Vught, L.E., Rose, M.R., Drost, G., van Engelen, B.G.M., van der Wilt, G.-J., The individualized neuromuscular quality of life questionnaire: cultural translation and psychometric validation for the Dutch population. Muscle Nerve 51 (2015), 496–500, 10.1002/mus.24337.
    • (2015) Muscle Nerve , vol.51 , pp. 496-500
    • Seesing, F.M.1    van Vught, L.E.2    Rose, M.R.3    Drost, G.4    van Engelen, B.G.M.5    van der Wilt, G.-J.6
  • 103
    • 84901940152 scopus 로고    scopus 로고
    • Long-term follow-up of 62 patients with myositis
    • [103] Van de Vlekkert, J., Hoogendijk, J.E., de Visser, M., Long-term follow-up of 62 patients with myositis. J Neurol 261 (2014), 992–998, 10.1007/s00415-014-7313-z.
    • (2014) J Neurol , vol.261 , pp. 992-998
    • Van de Vlekkert, J.1    Hoogendijk, J.E.2    de Visser, M.3
  • 104
    • 84888988753 scopus 로고    scopus 로고
    • Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup
    • [104] Alemo Munters, L., Dastmalchi, M., Andgren, V., et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup. Arthritis Care Res 65 (2013), 1959–1968, 10.1002/acr.22068.
    • (2013) Arthritis Care Res , vol.65 , pp. 1959-1968
    • Alemo Munters, L.1    Dastmalchi, M.2    Andgren, V.3
  • 105
    • 84895423757 scopus 로고    scopus 로고
    • Patient-reported outcomes and adult patients’ disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 myositis special interest group
    • [105] Alexanderson, H., Del Grande, M., Bingham, C.O., et al. Patient-reported outcomes and adult patients’ disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 myositis special interest group. J Rheumatol 41 (2014), 581–592, 10.3899/jrheum.131247.
    • (2014) J Rheumatol , vol.41 , pp. 581-592
    • Alexanderson, H.1    Del Grande, M.2    Bingham, C.O.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.